We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Agrees to Pay $2.3 Billion for Bextra Promotions
Pfizer Agrees to Pay $2.3 Billion for Bextra Promotions
January 30, 2009
Pfizer had a $2.3 billion expense in its fourth quarter for settling allegations that it promoted off-label use of its Cox-2 inhibitor pain drug Bextra — just a few months after it recorded a $900 million cost related to Cox-2 product liability litigation.